MYC (Myc proto-oncogene protein) variants and mutations

MYC (also known as Myc proto-oncogene protein) is a human protein-coding gene encoding a myc proto-oncogene protein. It activates broad transcriptional programs for ribosome production, metabolism, biomass accumulation, and cell-cycle progression. Translocation, amplification, or other persistent activation is a central driver of many cancers, including the hallmark MYC rearrangements of Burkitt lymphoma. This analysis covers 1,872 MYC variants and mutations. Of these, 38% have computational variant effect predictions. Disease context includes Burkitt lymphoma, neurodegenerative disease, and urinary bladder carcinoma. Example MYC variants include D2G, D2H, and D2Y.

Variant analysis overview

Variant and mutation evidence

Clinical, disease, and population context

Protein structure and variant hotspots

Data sources

Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.

Notable MYC variants

Examples include D2G, D2H, D2Y, F3L, R5G, R5L, R5P, R5Q. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.